×
About 873 results

ALLMedicine™ Immunofixation Center

Research & Reviews  262 results

Combined crystal-storing histiocytosis, light chain proximal tubulopathy, and light cha...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848311
Renal Failure; Zhu L, Wang L et. al.

Jan 13th, 2023 - Crystal-storing histiocytosis (CSH), light chain proximal tubulopathy (LCPT), and light chain crystalline podocytopathy (LCCP) are rare complications of multiple myeloma (MM) or monoclonal gammopathy of renal significance, and their diagnoses are ...

Multiple Myeloma Workup
http://emedicine.medscape.com/article/204369-workup

Jan 13th, 2023 - Approach Considerations The International Myeloma Workshop developed guidelines for standard investigative workup in patients suspected to have multiple myeloma. These guidelines include the following: [1] Serum and urine assessment for monoclonal...

Multiple Myeloma Guidelines
https://emedicine.medscape.com/article/204369-guidelines

Jan 13th, 2023 - Guidelines Summary Diagnosis Similar recommendations for the standard investigational workup for suspected myeloma have been issued by the following organizations: International Myeloma Working Group [135] National Comprehensive Cancer Network (NC...

Non-invasive diagnosis of transthyretin cardiac amyloidosis utilizing typical late gado...
https://doi.org/10.1093/ehjci/jeac249
European Heart Journal. Cardiovascular Imaging; Slivnick JA, Alvi N et. al.

Jan 10th, 2023 - While cardiac magnetic resonance (CMR) is often obtained early in the evaluation of suspected cardiac amyloidosis (CA), it currently cannot be utilized to differentiate immunoglobulin (AL) and transthyretin (ATTR) CA. We aimed to determine whether...

Expert-Level Immunofixation Electrophoresis Image Recognition based on Explainable and ...
https://doi.org/10.1093/clinchem/hvac190
Clinical Chemistry; Hu H, Xu W et. al.

Dec 23rd, 2022 - Immunofixation electrophoresis (IFE) is important for diagnosis of plasma cell disorders (PCDs). Manual analysis of IFE images is time-consuming and potentially subjective. An artificial intelligence (AI) system for automatic and accurate IFE imag...

see more →

Guidelines  3 results

The evaluation of monoclonal gammopathy of renal significance: a consensus report of th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136169
Nature Reviews. Nephrology; Leung N, Bridoux F et. al.

Dec 5th, 2018 - The term monoclonal gammopathy of renal significance (MGRS) was introduced by the International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012. The IKMG met in April 2017 to refine the definition of MGRS and to update the diagnosti...

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210231
Haematologica Minnema MC, Kimby E et. al.

Oct 21st, 2016 - Bing Neel syndrome is a rare disease manifestation of Waldenström's macroglobulinemia that results from infiltration of the central nervous system by malignant lymphoplasmacytic cells. In this guideline we describe the clinical symptoms, as well a...

Consensus recommendations for standard investigative workup: report of the Internationa...
https://doi.org/10.1182/blood-2010-10-299529
Blood Dimopoulos M, Kyle R et. al.

Feb 5th, 2011 - A panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monocl...

see more →

Clinicaltrials.gov  22 results

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT03201250

Dec 23rd, 2022 - In the currently proposed phase I/II study, the investigators aim to treat patients with relapsed and/or relapsed refractory multiple myeloma (MM) who have progressed on carfilzomib-based therapy with an FDA approved c-MET inhibitor, cabozantinib....

Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT04624906

Nov 14th, 2022 - This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with WM. Patients will require a biopsy to confirm the pathology and molecular testing for MYD88, CXCR4 and P53 mutations. A bone marrow aspiration and b...

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
https://clinicaltrials.gov/ct2/show/NCT03376477

Sep 14th, 2022 - This is a single institution, three- arm, randomized controlled, Phase II study examining the clinical efficacy of an allogeneic GM-CSF secreting myeloma vaccine in combination with lenalidomide (with or without Prevnar) compared to lenalidomide a...

Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT03413800

Jul 22nd, 2022 - Myeloma patients in first relapse after sibling or unrelated donor allogeneic transplant willing to participate in this study will be screened for eligibility. After baseline evaluation including BM aspirate for plasma cell count, minimal residual...

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT05208086

Jul 21st, 2022 - To evaluate the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in Multiple Myeloma patients. 300 evaluable patients are required. For each of them, both spo...

see more →

News  62 results

Societal Determinants of Health in Multiple Myeloma
https://www.onclive.com/view/societal-determinants-of-health-in-multiple-myeloma

Oct 11th, 2022 - Transcript: Joseph Mikhael, MD: Excellent, that's helpful. On the subject of trying to figure out why and that is obviously this first module that we're looking at, Craig I'm going to turn to you for a moment because as a scientists we think mayb...

Biomarker-Directed Therapy in Multiple Myeloma Signals the Future of the Field
https://www.onclive.com/view/biomarker-directed-therapy-in-multiple-myeloma-signals-the-future-of-the-field

Sep 1st, 2022 - The biology of multiple myeloma has an evolving role in guiding research efforts involving diagnostic and prognostic capabilities of available biomarkers and related molecular pathways. Myeloma cells often have genetic abnormalities, and we often ...

Scattered Flesh-Colored Papules in a Linear Array in the Setting of Diffuse Skin Thickening
https://www.mdedge.com/dermatology/article/257482/dermatopathology/scattered-flesh-colored-papules-linear-array-setting
Catherine Grace P. Hobayan, BS, Madison Grinnell, MD et. al.

Aug 31st, 2022 - The Diagnosis: Scleromyxedema A punch biopsy of the upper back performed at an outside institution revealed increased histiocytes and abundant interstitial mucin confined to the papillary dermis (Figures 1 and 2), consistent with the lichen myxede.

Agent Orange Exposure, Transformation From MGUS to Multiple Myeloma, and Outcomes in Veterans
https://www.mdedge.com/fedprac/avaho/article/256893/multiple-myeloma/agent-orange-exposure-transformation-mgus-multiple
Jyothi Dodlapati, MD, James A. Hall, DO et. al.

Aug 9th, 2022 - Multiple myeloma (MM) accounts for 1% to 2% of all cancers and slightly more than 17% of hematologic malignancies in the United States. 1 MM is characterized by the neoplastic proliferation of immunoglobulin (Ig)-producing plasma cells with ≥ 10% c.

Updated Progression-Free Survival and Depth of Response in IKEMA, a randomized phase 3 trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma
https://www.onclive.com/view/updated-pfs-and-dor-in-ikema-a-randomized-phase-3-trial-of-isatuximab-carfilzomib-and-dexamethasone-isa-kd-vs-kd-in-relapsed-mm

Jul 8th, 2022 - Background Isatuximab, (Isa), an IgG1 monoclonal antibody targeting a specific epitope of the CD38 transmembrane glycoprotein in MM, has multiple mechanisms of action: ADCC, CDC, and ADCP Direct apoptosis Immunomodulation Inhibition of ectoen...

see more →